Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 3

MARRONE BIO INNOVATIONS INC

Form 3

August 01, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Pitts Keith

(Last)

(First) (Middle)

Statement

(Month/Day/Year)

08/01/2013

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

MARRONE BIO INNOVATIONS INC [MBII]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O MARRONE BIO INNOVATIONS, INC., Â 2121 SECOND STREET, SUITE A-107

(Street)

(Check all applicable)

See Remarks

Director _X__ Officer

10% Owner Other (give title below) (specify below)

6. Individual or Joint/Group

Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

DAVIS, CAÂ 95618

(City) (State) (Zip)

1. Title of Security (Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

SEC 1473 (7-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of

information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. 5. Ownership Conversion or Exercise Form of

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Price of Derivative Derivative Security:

Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	07/21/2018	Common Stock	15,931	\$ 0.47	D	Â
Stock Option (Right to Buy)	(2)	01/28/2019	Common Stock	4,779	\$ 1.19	D	Â
Stock Option (Right to Buy)	(3)	01/11/2020	Common Stock	4,779	\$ 1.19	D	Â
Stock Option (Right to Buy)	(4)	01/11/2020	Common Stock	4,779	\$ 1.19	D	Â
Stock Option (Right to Buy)	(5)	01/24/2021	Common Stock	17,620	\$ 1.19	D	Â
Stock Option (Right to Buy)	(6)	12/15/2021	Common Stock	15,931	\$ 1.41	D	Â
Stock Option (Right to Buy)	(7)	02/20/2022	Common Stock	11,487	\$ 3.11	D	Â
Stock Option (Right to Buy)	(8)	10/18/2022	Common Stock	23,897	\$ 12.08	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Pitts Keith					
C/O MARRONE BIO INNOVATIONS, INC.	Â	Â	See Remarks	Â	
2121 SECOND STREET, SUITE A-107	11	7.1	71 See Remarks	11	
DAVIS, CA 95618					

Signatures

/s/ Donald J. Glidewell, Donald J. Glidewell, Attorney-in-Fact

08/01/2013

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of July 1, 2008, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
- The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2009, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
- (3) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2010, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
- (4) The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2010.

Reporting Owners 2

Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 3

- (5) The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2011.
- (6) The options vest with respect to 1/60th of the total shares subject to the option one month after the vesting commencement date of November 1, 2011, and 1/60th of the total shares subject to the option monthly thereafter for 36 months.
- (7) The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of February 20, 2012.
- (8) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of October 18, 2012, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.

Â

Remarks:

Vice President of Regulatory and Governmental Affairs

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.